An interesting summary of two FDA-cleared gene therapies for b-thalessemia and Cerebral adrenoleukodystrophy (CALD). ow.ly/B7hT50MimGK #genetherapy #andelyn

The new Andelyn Corporate Center (ACC) has 14 upstream rooms and the downstream and support rooms to meet the demanding needs of the gene therapy community. ow.ly/KgIo50Mip9u This is just a part of what makes Andelyn your trusted team in Gene Therapy manufacturing.

Exciting news for the treatment of hemophilia B. Pfizer has announced positive results from their phase 3 study of Fidanacogene elaparvovec, an investigational AAV vector containing a high-activity human coagulation FIX gene. ow.ly/jrKN50Mjlhp #aav #genetherapy #andelyn

Andelyn Biosciences is the pioneer in cell and gene therapy. Here are a few reasons why Andelyn is your trusted expert! Learn more: ow.ly/yocU50MjlXP

UMass Chan Medical School has established the Translational Institute for Molecular Therapeutics to advance gene therapy development. Current clinical trials include therapeutics for Tay-Sachs disease and amyotrophic lateral sclerosis (ALS). ow.ly/PYOP50Mjluy

A new marketing report estimates that the gene therapy market will surpass $3.25 Billion (USD) by 2030 with a CAGR of 19.1%! ow.ly/cbEu50Mk1fG #genetherapy #andelyn

**Event Alert** Andelyn Biosciences will be attending Advanced Therapies Week from January 17-20, 2023, at the Miami Beach Convention Center! Follow our LinkedIn page to keep up to date about this upcoming event! ow.ly/M7Gk50Mk1hI

Experts from Andelyn Biosciences give their perspectives on challenges and opportunities in the industry. ow.ly/CQrV50Mk1Km

Gene editing treatments are looking promising for the treatment of some forms of ALS. A CRISPR/Cas9 system delivered by AAVs was used to remove the repeat expansion C9ORF72 gene (the most common genetic cause of ALS) in both mice and human cells. alsnewstoday.com/news/crispr-ca…

Nice to see gene therapies on a list of FDA-approved drugs in 2022. Three that were approved this year treat rare diseases bringing the total to five! We can’t wait to usher in more gene therapy treatments. #genetherapy #andelyn nature.com/articles/d4157…

Andelyn Biosciences utilizes the latest manufacturing optimization tools to maximize efficiencies and accelerate timelines. Speak with an expert or learn more: ow.ly/fFjc50Mmiuu #GeneTherapy #CDMO #genetherapymanufacturing #clinic #andelyn #viralvectormanufacturing

Opus has acquired two new AAV-based gene therapy candidates for inherited retinal disease. 2023 should be an exciting year for gene therapies for retinal diseases! ow.ly/7zfj50Mni3t #genetherapy #andelyn

Andelyn Biosciences deep expertise in both innovation and tech transfers allows for tremendous flexibility for adherent and suspension based manufacturing at scales from 1L to 2000L. ow.ly/Kbxw50MnigP

An interesting article about 4D Molecular Therapeutics. They are developing gene therapies for ophthalmology, cardiology, and pulmonology using a novel AAV vector platform. ow.ly/VaAA50Mpe2o #genetherapy #andelyn #aav

**Event Alert** Andelyn Biosciences will be attending Advanced Therapies Week from January 17-20, 2023, at the Miami Beach Convention Center! Follow us on Twitter to keep up to date about this upcoming event! advancedtherapiesweek.phacilitate.com

The Andelyn Development is the home of Andelyn’s research, process development, and analytical development, expanding Andelyn’s capabilities and meeting client demand! ow.ly/B5cY50Mpgmy

View Andelyn Biosciences special edition feature in BIOPROCESS ONLINE. Facilitate and Implement Rapid Process Changes In Gene Therapy Manufacturing! ow.ly/ZJg350MqmeL

With 20+ years of experience manufacturing viral vectors, Andelyn’s scientific expertise for development and characterization has led to GMP material being produced for over 75+ worldwide clinical trials and 400+ cGMP clinical batches. ow.ly/OUZe50MqrVx

Team Andelyn is down at Phacilitate Miami! Come see us at booth #311! #AndelynBio #AndelynBiosciences #Phacilitate #advancedtherapies #celltherapy #genetherapy #cellandgenetherapy #powerofpartnerships #advancedtherapiesweek

4/8 Battelle, @Amplify_Bio, and Andelyn Biosciences win $149m contract from National Institute of Neurological Disorders to develop advanced therapies to treat neurological conditions. endpts.com/three-ohio-bas…